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Background: Treatment of subclinical mastitis during lactation can have both direct (individual animal level) and
indirect (population level) effects. With a few exceptions, prior research has focused on evaluating the direct effects
of mastitis treatment, and to date no controlled field trials have been conducted to test whether beneficial indirect
effects of lactation treatment strategies targeting subclinical mastitis can be demonstrated on commercial dairy
farms. Furthermore, there is limited knowledge on the impact of such interventions on the population dynamics of
specific bacterial strains. The purpose of this study was to test the hypothesis that lactation therapy targeting S.
aureus subclinical intramammary infection reduces transmission of S. aureus strains within dairy herds. Pulsed-field
gel electrophoresis (PFGE) and multilocus sequence typing (MLST) were used to determine strain specific infection
dynamics in treated and control groups in a split herd trial conducted on 2 commercial dairy farms.
Results: The direct effect of 8 days intramammary lactation therapy with pirlimycin hydrochloride was
demonstrated by an increased proportion of cure and a reduction in duration of infection in quarters receiving
treatment compared to untreated controls. The indirect effect of lactation therapy was demonstrated by reduction
of new S. aureus intramammary infections (IMI) caused by the dominant strain type in both herds. Strain typing of
representative isolates taken over the duration of all IMI, including pre- and post-treatment isolates, provided more
precise estimates of new infection, cure, and re-infection rates. New S. aureus infections in recovered susceptible
quarters and the emergence of a new strain type in one herd influenced incidence measures.
Conclusion: In addition to demonstrating positive direct effects of lactation therapy, this study provides evidence
that treatment of subclinical S. aureus mastitis during lactation can have indirect effects including preventing new
IMI and reducing incidence of clinical mastitis within dairy herds. Strain specific transmission parameter estimates
for S. aureus MLST clonal complexes 5, 97 and 705 in 2 commercial dairy herds are also reported.
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Mastitis continues to be recognized as one of the most
economically important health problems of dairy cattle
[1,2]. Subclinical mastitis, which can be characterized by
an elevated milk somatic cell count (SCC), is the domi-
nant form affecting cows. A number of authors have sug-
gested that dairy producers frequently leave subclinical
mastitis undetected or untreated for extended periods
during lactation [3-5].* Correspondence: john.barlow@uvm.edu
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reproduction in any medium, provided the orMastitis control interventions are intended to reduce
the duration of infection and prevent new infections.
Examples of effective mastitis control practices include
the use of long acting antibiotics at the end of lactation
(dry-cow therapy), application of a post-milking teat disin-
fectant following each milking, and segregation or culling
of infected individuals [6,7]. Treatment of mastitis during
lactation has been predominately limited to the treatment
of clinical cases, although the value of treating subclinical
mastitis during lactation is well recognized as a component
of Streptococcus agalactiae control [8]. The potential impact
of lactation therapy on transmission of other major gram-
positive mastitis pathogens (e.g. Staphylococcus aureus andLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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tical model which accounted for both direct and indirect
effects of treatment [9]. Previous field studies have exa-
mined the direct effect of lactation therapy for subclinical
mastitis [10,11]. Delaying successful treatment of subclinical
S. aureus IMI may increase the duration of infection, reduce
the probability of cure and increase the risk of exposure for
uninfected quarters [12,13]. Therefore, successfully treating
cases of subclinical mastitis has a direct effect on the trea-
ted animal, but may also have an indirect effect by redu-
cing new infection risk in uninfected animals in the herd
[9,13,14]. To date no controlled field trials have been
conducted to test whether the predicted beneficial indirect
effects of subclinical mastitis lactation treatment strategies
can be demonstrated on commercial dairy farms. Further-
more, there is limited knowledge on the impact of such
interventions on the population dynamics of specific
bacterial strains. For example, S. aureus strains may be
identified using molecular methods including pulsed-field
gel electrophoresis (PFGE) and multilocus sequence typ-
ing (MLST), and strain specific differences in clinical
manifestations, host-adaptation, and response to therapy
have been identified [13,15,16].
In this report we describe the results of a field trial that
evaluated a diagnosis driven treatment program targeting
subclinical S. aureus IMI and applied PFGE and MLST to
identify strain specific S. aureus infection dynamics. Out-
comes evaluated in this study included cure proportions,
duration of infection, infection prevalence and incidence,




A negative-controlled treatment trial was conducted for a
period of 13 months on 2 commercial dairy herds (one
each in New York and Vermont, USA) milking Holstein
dairy cows 3 times per day in a milking parlor (Table 1).
Criteria for herd participation included: 1) reliable individ-
ual cattle identification; 2) housing of lactating dairy cattle
in two or more comparable groups (“strings”) of approxi-
mately 100 cows in separate pens (free-stall housing);
3) enrolled in a Dairy Herd Improvement Association
(DHIA) monthly testing program including SCC; 4) an
average monthly herd SCC between 250,000 and 500,000
cells/ml; 5) accepted mastitis control practices applied to
all cows, including use of pre- and post-milking teat disin-
fectants, and blanket use of dry-cow therapy; 6) segregated
housing for lactating cows receiving antibiotic treatments;
7) owner willing to keep records on all cows, including
dates of calving, entries and exits from lactating cow pen
groups, clinical disease, treatment, and culling. Herd ow-
ners were compensated for participation in the study. The
study was conducted with approval of the CornellUniversity and University of Vermont Institutional Animal
Care and Use Committees (IACUC).
Treatment was randomly allocated to one of 2 pens
within each herd and the treatment unit was a group
(pen) of lactating cows. In the month preceding the start
of the study, cows were systematically assigned to pens
based on existing odd or even unique identification
numbers. Cows that calved during the study were
assigned to either the treatment or control pens based
on their odd-even identification number. Using this
randomization method no differences in mean parity,
days in milk, or SCC, were found among treatment and
control groups within herds at the start of the study.
Groups within herds were a dynamic population, with
entries and exits of individuals into the study population
following normal management cycles. Dates of all entries
and exits to treatment or control pens were recorded for
each cow. Pens of cows within each herd were milked in
the following order at each milking session: fresh cow
group (cows < 30 days in milk), study treatment group,
study control group, additional pens not enrolled in
study. The milking system was washed and sanitized
3 times daily between each milking of the entire herd.
Milk sample collection and bacteriologic analysis
Composite milk samples were collected monthly by DHIA
technicians and processed through regional commercial
testing laboratories for SCC testing. Individual quarter
milk samples were collected for microbiologic analysis
from all cows in control and treatment groups at the start
of the study, at monthly intervals for the duration of the
study, and at the end of the study. These quarter samples
were collected within 3 days of DHIA monthly composite
sample collection. Quarter milk samples were also col-
lected from all cows within 3 days following parturition
(fresh sample), immediately following identification of
clinical mastitis (clinical pre-treatment sample), immedi-
ately prior to treatment of subclinical mastitis (subclinical
pre-treatment sample), at any time when cows were added
to or removed from the study pens for greater than
24 hours (entry/exit sample), immediately prior to exit
from the herd (cull sample), and at approximately 7, 14,
21, and 28 days following cessation of any antibiotic ther-
apy (clinical or subclinical post-treatment samples).
Monthly sample collection was conducted by trained field
technicians, while farm personnel were trained to collect
all additional samples using aseptic methods [18]. All sam-
ples were stored frozen for up to 2 weeks prior to being
thawed over-night under refrigeration for aerobic bacte-
riologic culture (10 uL of each milk sample plated on
tryptic soy agar with 5% sheep’s blood and 1% esculin
plate and incubated for up to 48 hours at 37°C). Interpre-
tation of culture results was performed according to estab-
lished guidelines [18]. Samples with ≥3 morphologically


























Number S. aureus isolates (# quarters/# cows)
IMI associated isolates3 incidental isolates3
1 treatment 95 31.4 419 129984 1335 80(21/20) 15(13/11)
control 98 32.7 401 130254 2479 137(25/21) 22(20/17)
whole herd4 319 32.7 404 221(50/45) 37(33/28)
2 treatment 91 42.3 292 125241 1345 58(11/9) 2(2/2)
control 89 41.4 296 116295 14 1(1/1) 0
whole herd 346 35.0 298 68(21/16) 4(4/4)
1 Sum of individual quarter days uninfected at risk for new intramammary infection (IMI).
2 Sum of individual quarter days infected based on midpoint estimates of IMI start and stop dates [17].
3 IMI status based on definitions of Zadoks et al. [12]; incidental isolates are those not meeting IMI criteria.
4 Whole herd totals include all lactating cows during study period, (cows that entered treatment and control groups, plus cows never housed with these groups);
number of isolates obtained from whole herd exceeds sum of treatment and control pens as 13 IMI isolates and 2 incidental isolates were obtained from milk
samples collected from cows sampled at the start of a lactation and either the IMI cured prior to entry into a study pen or the cow did not enter a study pen
during the course of the trial.
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eliminated from analysis.
Infection status
Sequential SCC measurements in combination with bac-
teriologic culture were used to identify cows with subclin-
ical IMI and eligible for lactation therapy. This procedure
was intended to model a practical culture-based diagnostic
program that might be applied on commercial farms
where an elevated composite cow-level SCC is used to
trigger quarter-level bacteriologic culture and culture
results are used to trigger a decision to intervene (for
example treat, segregate or cull the infected quarter or
cow). Sequential cow level SCC was evaluated to identify
cases of subclinical mastitis which were defined as com-
posite milk SCC ≥ 200,000 cells/ml for 2 or more serial
monthly samples. Sequential quarter level bacteriologic
culture was used to define IMI status. Throughout this
report, we use the term “subclinical mastitis” to describe
cases of mastitis defined by SCC measures, and “IMI” or
“subclinical IMI” to describe cases of mastitis defined by
bacteriologic culture. An individual quarter was defined as
having a subclinical IMI, when having no occurrence of
clinical mastitis within the previous 14 days and meeting
the criteria of Zadoks et al. [12] (i.e. ≥ 1000 CFU/ml of
S. aureus cultured from a single sample, ≥ 500 CFU/ml of
S. aureus cultured from two out of three consecutive
samples, or ≥100 CFU/ml of S. aureus cultured from three
consecutive samples). Isolations of S. aureus from uncon-
taminated samples that did not meet these criteria were
defined as incidental isolation events. Cure of a subclinical
IMI following therapy was defined when a quarter was
culture negative for the pre-treatment species or strain on
4 of 4 weekly post treatment samples. An untreated quar-
ter with a subclinical IMI was defined as spontaneouslycured when the quarter was negative for the same species
or strain on 2 consecutive samples taken at least one
month apart. Clinical mastitis was defined as an abnor-
mality in appearance or consistency of milk, with or with-
out localized (e.g. swollen quarter) or systemic signs. A
clinical IMI was defined as a case of clinical mastitis with
a S. aureus positive bacteriologic culture (i.e. ≥100 CFU/
ml). A new clinical mastitis event was identified at the quar-
ter level after that quarter was observed free of clinical signs
for ≥ 14 days or if clinical mastitis occurred within 14 days
of a previous case but was caused by a different bacterial
species or strain. A clinical IMI was defined as a bacterio-
logically cured when culture negative for the pre-treatment
species or strain on 4 of 4 weekly post treatment samples.
These definitions recognize that quarters defined as having
a subclinical IMI could have sporadic clinical events, either
presenting as clinical flare-ups during a subclinical IMI or
as an initial clinical event which subsequently becomes a
subclinical case [12,14].
Treatment program
The objective of the diagnostic program was to target lac-
tation therapy to cows with subclinical S. aureus IMI.
Cows assigned to the treatment group were eligible for
lactation therapy if they had an elevated composite SCC
(≥200,000 cells/ml) in the current month, plus an elevated
SCC (≥200,000 cells/ml) in one of the two previous
months in combination with a S. aureus positive culture
result in at least one quarter in the current month. All
lactating quarters of eligible cows were treated, regardless
of the number of infected quarters, because there is a
within cow correlation of infection risk among quarters
[19]. Treatment of all 4 quarters in infected cows thus
decreased the potential effect of within cow interdepen-
dence of quarters on transmission and incidence estimates.
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lactation was not intended to model a recommended prac-
tice for adoption by commercial dairy producers. Treatment
was with a commercially available intramammary formula-
tion of pirlimycin hydrochloride (Pirsue™, Pfizer Animal
Health, New York, USA) at the labeled dosage (50 mg) once
daily for 8 days [10]. Cows diagnosed with subclinical IMI
in the control group received no therapy. Cows experien-
cing clinical mastitis in either group were treated using the
established practices of the participating farms and records
were maintained on the type and duration of therapy. Dur-
ing a 3-month ‘pre-intervention’ observation period at the
start of the study there was no treatment of subclinical mas-
titis in the treatment group. All data were collected during
both the initial 3 month observation and the subsequent
10 month intervention periods.
Species identification and S. aureus strain typing
Presumptive Staphylococcus spp. colonies were identified
based on growth characteristics, and were transferred to a
blood agar plate for isolation and further identification.
All catalase-positive, hemolytic, gram-positive cocci were
tested for coagulase activity by the tube coagulase test
[18]. Coagulase-positive gram-positive cocci were trans-
ferred to broth culture and stored at −80°C on ceramic
beads (CryoBank beads, Copan Diagnostics Inc., Murrieta,
CA) in tryptone soy broth with 15% glycerol. All stored
coagulase-positive staphylococci were tested by PCR amp-
lification of the S. aureus specific thermonuclease gene
(nuc) using established methods to confirm species iden-
tity [20]. Within each IMI, representative S. aureus isolates
were selected from storage for strain typing by PFGE and
MLST. In quarters having more than one isolation event
over time, isolates were selected for strain typing from
early (e.g. the first isolation event), middle (one or more
subsequent isolation events), and late (one of the final
isolation events) time points. In addition, pre- and post-
treatment isolates were selected for strain typing from all
cows receiving lactation therapy.
PFGE typing was conducted as described by McDougal
et al. [21]. PFGE pulsotypes (PTs) were identified by visual
examination of gels by two independent observers (JWB
and RNZ) using established criteria [22] with different
types identified by > 3 band differences on restriction
digest patterns. Isolates that differed by 1 to 3 bands were
defined as a subtype. MLST was conducted as described
by Enright et al. [23] with alleles, sequence types (ST), and
clonal complexes (CC) assigned using the MLST database.
Novel alleles and STs (allelic profiles) were assigned desig-
nations by the database curator following submission of
DNA sequence trace chromatograms (www.mlst.net).
Clonal complexes and new STs were defined as bovine- or
human-adapted using methods described by van den
Borne et al. [16].Susceptibility testing for the antimicrobials ampicillin,
cephalothin, ceftiofur, erythromycin, oxacillin, pirlimycin,
penicillin, penicillin/novobiocin, and tetracycline was con-
ducted on isolates selected for strain typing using broth
micro-dilution minimum inhibitory concentration meth-
ods (MIC; Sensititre, Trek Diagnostic Systems, Cleveland,
Ohio, USA) following Clinical Laboratory Standards Insti-
tute (CLSI) standards [24]. MIC50 and MIC90 values were
calculated for any PT or ST with 3 or more IMI using the
methods of Schwarz et al.[25]. Presence of genetic markers
associated with penicillin resistance (blaZ) and methicillin
resistance (mecA) were tested by PCR using established
methods [26,27] for all isolates selected for strain typing,
and these isolates were also screened for beta-lactamase
expression using a nitrocefin assay [28].
Duration of infection
Duration of infection was calculated based on the mid-
point estimation method previously described by Zadoks
et al. [17]. Infected quarters entering the study, either at
the start of the study or at the start of a lactation, were
considered left censored and the IMI start date was the
date of first positive culture. Infected quarters exiting
the study were considered right censored and the IMI
end date was the date of exit or the end date of the
study. Quarter days infected at pen or herd level (i.e. the
sum of IMI prevalence days for individual quarters of all
animals) were calculated based on recorded dates of cow
entry and exit from the study pens for all lactating quar-
ters. Quarter days susceptible (i.e. days at risk for new
IMI among uninfected quarters) were calculated based
on recorded dates of cow entry and exit from the study
pens accounting for the date of change in quarter infec-
tion status during each interval. Non-lactating quarters
in lactating cows were identified with the date of milking
cessation of the individual quarters (i.e. quarter ‘culling’)
so that any ‘blind’ or culled quarters within lactating
cows did not contribute to the number of infected or
susceptible quarter days in the pen or herd.
Statistical methods
All statistical analysis was conducted using SAS version
9 (SAS Institute, Inc., Cary, NC, USA). Difference in the
proportion of quarters cured in treatment groups was
tested using Fisher’s exact test. Pearson chi square or
Fisher’s exact test were used to test for associations
between treatment group and the proportion of quarters
becoming re-infected following cure, or the proportion
of quarters with at least one clinical mastitis event, or
the proportion of quarters culled due to mastitis. The
proportion of S. aureus clinical mastitis events was ana-
lyzed using two measures, either as a count of quarters
with at least one clinical mastitis event to eliminate poten-
tial bias associated with repeated events within a quarter,
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that treatment affected duration of infection was tested
using the Log-rank test to compare the Kaplan-Meier sur-
vival function for S. aureus IMI in treatment and control
groups, while controlling for the effect of PT or ST. We
also modeled the effect of treatment on duration of infec-
tion using a linear regression model including PT or ST as
a covariate.
Prevalence of S. aureus IMI (number of quarters days
infected, PI ), and incidence of new S. aureus IMI (num-
ber of new IMI, IN ), were analyzed as outcomes using
generalized linear models (PROC GENMOD, SAS) and
model checking included examination of deviance and
Pearson Chi-square for goodness of fit [12,29]. Evidence
of overdispersion was adjusted using Pearson Chi-square
estimates divided by the degrees of freedom (Pscale
option). Binomial, Poisson, or Negative Binomial error
distributions were selected for final models after com-
parisons for goodness of fit. Backward elimination of
variables was used to select the final models with trea-
tment group (Group), the primary effect of interest,
forced into all final models. Additional independent var-
iables and their 2- and 3-way interactions where
included when p<0.10. Additional variables included in
the full models were farm, time period (Timep), and PT
or ST when prevalence was the dependent variable, and
these same variables plus prevalence (PI) when incidence
was the dependent variable. Time period was modeled
with 2 categories defining the pre-intervention (observa-
tion months 1–3) period as 0 and the intervention
period (months 4–13) as 1. Because we observed diffe-
rences in strain dynamics over time during the interven-
tion period, we also modeled time period with 3
categories, by separating pre-intervention (pre, months
1–3), early intervention (earlytp, months 4–8) and late
intervention (latetp, months 9–13) periods. In the final
prevalence model, the impact of treatment group on the
prevalence in each interval was modeled assuming a
negative binomial error distribution, a log link, and an
offset of the total number of quarter days,
ε ln PIð Þ½  ¼ intcpt þ Groupþ Timep
þ GroupTimepþ ln Nð Þ ð1:1Þ
where ε = expected value and ln(N)= offset. Compari-
sons of least square means IMI quarter-days prevalence
(PI) between treatment and control groups and across
time periods was conducted separately for each farm
using model 1.1 and accounting for multiple compari-
sons with Bonferroni methods.
The impact of treatment on incidence in each interval
was estimated in a Poisson regression model, with a
Poisson error distribution, a log link, and an offset of the
number of quarter days susceptible for new IMI (S),ε ln INð Þ½  ¼ intcpt þ Groupþ Timep
þ GroupTimepþ ln Sð Þ ð1:2Þ
Since prevalence was affected by treatment group (co-
variance estimate = 0.46, p=0.018), prevalence was not
included as a covariate in model 1.2.
Transmission parameters (βi) were estimated from a
generalized linear model with number of new IMI events in
each monthly interval (IN) as the outcome, a log link,
assuming a Poisson error distribution, and offset ln (S*I/N)
[12,29],





where β*= ln(β), S = quarter days susceptible, I = quarter
days infected, and N = total quarter days in each interval.
Separate transmission parameters (including 95% confi-
dence intervals) were estimated for the individual farms, as
well as between treatment periods, groups, and for STs. The
univariate effects of farm, treatment group, time period, and
ST on transmission parameter estimates were estimated by
inclusion of these variables in model 1.3.
Results
Descriptive analysis
A total of 31,761 quarter milk samples were collected
from the two herds, with S. aureus isolated from 330 sam-
ples. From Herd 1, there were 14,467 quarter samples
taken from 3675 sample events from 385 cows, with 209
(1.4%) samples identified as contaminated leaving 14,258
quarter samples for analysis. Of these, S. aureus was iso-
lated from 258 (1.8%) samples. From Herd 2, there were
17,294 quarter samples taken from 4387 sample events
from 580 cows, with 787 (4.6%) samples identified as con-
taminated leaving 16,507 quarter samples for analysis. Of
these, S. aureus was isolated from 72 (0.4%) samples.
S. aureus was not identified in any samples classified as
contaminated from either herd. Table 1 summarizes the
herd production, SCC, and S. aureus IMI data by trea-
tment group within herd.
Strain typing
Nine PTs were recognized to cause S. aureus IMIs, with
up to 3 subtypes identified within 4 of the PTs (Table 2).
Twelve STs were identified in these herds including STs
in bovine host-associated CCs 97, 479, and 705, and
human host-associated STs 8, 20, 25, and 87. Four pre-
viously unreported alleles and 3 new STs were identified
and clustered within CCs 97 and 705 (Table 2).
Infection due to a single strain or subtype over time
was common. Serial sampling showed a single strain to
be associated with 37 of 38 IMI. Strain typing was com-
pleted on 2 to 4 (mean =2.1) pretreatment isolates
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and 2 to 6 (mean = 3.6) isolates from infected quarters
of cows in the control group. Strain typing identified
3 quarters where a difference in the strain was observed
between pre-treatment and post-treatment isolates.Table 2 Strain typing of 171 selected Staphylococcus aureus i
Strain type IMI5 Herd In vitro Antimicrobial Susceptibility-
PT2 ST3 MLST
CC4
Amp Ceph Ceftio Ery










1a 2185 705 1 1 ≤0.12 ≤2 1 ≤0.25












1c nd 1 1 ≤0.12 ≤2 1 ≤0.25
2 2189 97 5 1 ≤0.12/
≤0.12
≤2/8 1/1 ≤0.25





2a nd 1 1 ≤0.12 ≤2 2 ≤0.25






3 8 5 7 2 0.5/0.5 ≤2/
≤2
1/1 ≤0.25/≤
4 352 97 2 2 ≤0.12 ≤2 2 ≤0.25
4a 352 97 5 2 ≤0.12/
≤0.12
≤2/4 1/1 0.5/0.
4bfh nd 1 1 ≤0.12 ≤2 1 0.5
5 2187 97 1 1 ≤0.12 ≤2 1 ≤0.25
5a nd 1 1 ≤0.12 ≤2 1 ≤0.25
6 nd 1 1 ≤0.12 ≤2 ≤0.5 ≤0.25
7 20 20 1 2 ≤0.12 ≤2 ≤0.5 ≤0.25
8 479 479 1 1 ≤0.12 ≤2 ≤0.5 ≤0.25
9† 87 59 0 1 8 4 2 8
10 25 15 1 3 16 ≤2 1 ≤0.25
11† nd 0 2 ≤0.25 ≤2 ≤0.5 ≤0.25
1 Isolates from 74 IMI including 61 IMI identified in cows in treatment and control p
10 incidental isolates were also typed.
2 PFGE pulsotypes; types with the same number but different letters are minor vari
3 Sequence type determined by MLST.
4 MLST clonal complex predicted founder determined by eBurst MLST database (las
5 Number of quarters with IMI for each strain type.
6 Antimicrobial susceptibility for ampicillin (Amp), cephalothin (Ceph), ceftiofur (Cef
(Pen:Novo), pirlimycin (Pirl), and tetracycline (Tet); MIC50 and MIC90 values calculate
† type found as only an incidental isolate, not defined as IMI or associated with sub
fh type found in fresh heifer with clinical mastitis, cow did not enter study pens.
nd = not determined.These quarters were culture negative for 2 and 3 weeks
post treatment before a new S. aureus strain was isolated.
There was 100% agreement between phenotypic and
genotypic test results for penicillin and oxacillin suscep-
tibility. Antimicrobial resistance factors were associatedsolates from 2 herds1
































































































≤2 ≤0.12 ≤(1:2) ≤0.5 ≤1/
≤1
−/−
≤2 ≤0.12 ≤(1:2) ≤0.5 ≤1 −/−
≤2 ≤0.12 ≤(1:2) ≤0.5 ≤1 −/−
≤2 ≤0.12 ≤(1:2) ≤0.5 ≤1 −/−
≤2 0.25 ≤(1:2) ≤0.5 ≤1 −/−
≤2 ≤0.12 2/4 ≤0.5 ≤1 −/−
4 8 ≤(1:2) 1 2 +/+
≤2 8 ≤(1:2) ≤0.5 ≤1 +/−
≤2 0.25 ≤(1:2) ≤0.5 ≤1 −/−
ens and13 IMI identified in cows that did not enter study pens. An additional
ants with 1–3 band differences.
t searched May 30, 2012).
tio), erythromycin (Ery), oxacillin (Oxa), penicillin (Pen), penicillin:novobiocin
d as described in [25].
clinical mastitis (SCC< 200,000 cells/ml).
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gene PCR and showed increased ampicillin and penicil-
lin MICs, and ST 87 was positive for blaZ and mecA
gene PCR and had increased ampicillin, penicillin,
oxacillin and erythromycin MICs, compared to all other
strain types which had relatively low MIC values and
were blaZ and mecA gene PCR negative (Table 2).
Bacteriologic cure and the effect of lactation therapy on
clinical mastitis and culling
Table 3 summarizes results of subclinical IMI treated for
8 days with pirlimycin. Twenty-three (38%) of the 61 IMI
identified in the study pens were not eligible for 8-day
therapy. Reasons that IMI were not eligible for treatment
included short duration subclinical IMI not defined as
subclinical mastitis based on SCC measures (n=2), IMI
identified in the pre-intervention period that either spon-
taneously cured (n=3) or were right censored during the
pre-intervention period (n=6), and clinical IMI events that
either cured (n=4) or were culled or dried-off prior to
being defined as subclinical IMI (n=8). Re-infections with
S. aureus following cure were observed for 3 quarters.
There was a significant difference in the proportion of
quarters cured in the treated groups compared to control
groups using data from only Herd 1 or pooled from the 2
herds (p<0.001, Fischer exact test, exact confidence limits
undefined; Table 3). In Herd 1 the 10 subclinical IMI that
cured following 8-day therapy were caused by CC97 and
705 and in herd 2 the 4 subclinical IMI that cured were all
caused by ST8. Most (3 of 4) IMI defined as non-cured
IMIs were observed in herd 1 and caused by ST2185
(CC705).Table 3 Staphylococcus aureus IMI eligible for 8-day lactation
Treatment Pen




Farm 1 13 13 10 0 0 1
Farm 2 9* 5 4 3 1 1
Total 22 18 14 3 1 2
Control Pen
All Subclinical treated Spontaneous cure3 Right censor r
exit dry cull
Farm 1 16 nt4 0 0 6 1
Farm 2 0 nt 0 0 0 0
Total 16 nt 0 0 6 1
1 Bacteriologic cure following treatment of subclinical or clinical IMI is based on neg
samples taken at approximately 7, 14, 21, and 28 days post-treatment.
2 Right censored IMI are classified to include all IMI that are not cured prior to eithe
(cull), or at the conclusion of the study (study end).
3 Spontaneous cure of an IMI is based on 2 sequential negative monthly cultures fo
4 nt = not treated, i.e. subclinical IMI that would have been eligible for therapy in c
* 4 quarters in the treatment group were eligible for subclinical therapy but exited
1 dry-off).In Herd 1, the odds of a subclinical S. aureus IMI
displaying a clinical mastitis flare-up in the control group
were 22 times greater than in the treatment group
(p<0.001, Fischer exact test, exact confidence limits
3 <OR<239). The odds ratio was an unbiased estimate
based on data in Table 3, which are the number of quar-
ters with at least one clinical event ignoring repeated cli-
nical episodes within a quarter. However, 3 quarters in the
control group displayed recurrent clinical episodes, there-
fore the total number of clinical events observed were 2
among 13 S. aureus IMI in the treatment group compared
to 15 among 16 S. aureus IMI in the control group. No
clinical flare-ups of S. aureus mastitis were observed in
association with subclinical IMI in Herd 2, however there
were 4 clinical S. aureus IMI events in post-partum cows
that occurred while they were housed in fresh groups
(i.e. before they entered the treatment or control groups).
These clinical cases were caused by ST151 and ST352. In
Herd 1, there were 7 clinical S. aureus events not asso-
ciated with subclinical IMI, and all of these were caused
by ST2185.
There were fewer total right censored S. aureus IMI in
the treatment groups compared to the control groups but
there was no difference between groups in the proportion
of mastitis associated culling events (Table 3).
Direct effect of lactation therapy on duration of infection
The arithmetic mean duration of subclinical IMI calcu-
lated using the midpoint estimation method was 135 and
86 days for the control and treatment groups respectively.
Least square mean estimates of duration from a genera-
lized linear model accounting for the effect of treatmenttherapy in treatment and control pens
eason2 Quarter with Clinical events




eason2 Quarter with Clinical events




ative bacteriologic culture for the pre-treatment Pulsotype (PT) on 4 of 4
r exit from a study pen to another lactating group (exit), dry-off (dry), culling
r the prior PT.
ontrol pens but were not treated.
the study pen prior to initiation of therapy (3 exited to another pen and
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ment and strain, were similar to the values obtained using
the mid-point estimation method, and the effect of treat-
ment was significant (p=0.0072). In a Kaplan-Meier esti-
mate of the survival function of subclinical IMI accounting
for censored observations, the median duration of infection
was estimated to be 256 and 93 days in the control (n=16)
and treatment (n=22) groups respectively, demonstrating a
significant reduction in duration of infection in the groups
of cows receiving the intervention (log rank test p=0.0025,
Figure 1).
Effect of lactation therapy on IMI prevalence
Differences between treatment groups were observed for
the total number of infected quarter days in the two herds
(Table 1). In Herd 1, the mean prevalence per 10,000 cow
days for the pre-intervention time period (months 1–3)
did not differ between groups; however, differences in the
prevalence were evident in subsequent months in both
groups (Figure 2, top panels). In the pre-intervention
period (months 1–3) and the early intervention period
(months 4–9) new IMIs in the treatment group were
caused in approximately equal numbers by PT 1,1b, and
2, while in the late intervention period (months 10–13)
subtype 2b emerged. In the control group, prevalence of
PT 1 and 2 continued to rise steadily during the 13 months
of the study and subtype 2b also emerged in months 10 to
13, contributing to an overall higher prevalence in this
group compared to the treatment group (Figure 2).
In Herd 2, the reduction in prevalence over time was
evident in the treatment group (Figure 2). This was attri-
buted to cure of 4 IMI caused by ST8 and post-treatment
spontaneous cure of an IMI caused by ST25. These cures

















Figure 1 Kaplan-Meier survival function of subclinical staphylococcus
infection for 22 quarters in the treatment groups (dashed line) estimated to
estimate for 16 quarters in the control groups (solid line) demonstrating a
groups of cows receiving the intervention.months 9 and 10 which spontaneously cured by month
12. Because there were so few S. aureus infections in the
control pen, comparison of treatments on farm 2 was not
possible, and we subsequently modeled the effect of treat-
ment on prevalence using only the subset of data for Herd
1 in model 1.1. In the final linear model the interaction
between time period and treatment group was significant,
and the effect of treatment was a significant reduction in
prevalence in the treated group in the early intervention
period.
Effect of lactation therapy on IMI incidence
There were a total of 42 new IMI per 501,774 quarter
days at risk, with 36 new IMI observed in Herd 1 and 6
new IMI in Herd 2. When modeling incidence of new
IMI in Herd 1 (model 1.2) there was no convergence in
a full model due to over-parameterization of the data
available for effect estimation. In a reduced model, treat-
ment group and time period specific incidence estimates
were obtained using the treatment group by time inter-
actions and the effect of treatment was a significant
reduction in incidence of new infections in the treated
group in the early intervention period.
S. aureus transmission parameter estimates
The transmission parameter (β) estimates (including 95%
confidence interval lower and upper limits) for S. aureus
from the full data set and for each individual farm were: all
data, β = 0.00710 (0.00495 – 0.01019); farm 1, β = 0.00804
(0.00557 – 0.01161); farm 2 β = 0.00448 (0.00147 –
0.01369). Strain was the only statistically significant covari-
ate in model 1.3. The bovine associated CC705, which
includes ST151, had a significantly increased transmission
parameter, [β = 0.01038 (0.00718 – 0.01499)] compared totion (days)
200 250 300 350 400
Control group
Treatment group
aureus IMI from 2 commercial dairy herds. The median duration of
be 93 days was less than the 256 day median duration of infection
reduction (log rank test p=0.0025) in duration of infection in the
Figure 2 Staphylococcus aureus intramammary infections (IMI) on two farms over 13 months. Total prevalence (data points on line)
expressed as number of days infected per 10,000 quarter days (right axis). Number new IMI from naïve susceptible quarters (S) and number new
IMI from recovered susceptible quarters (R) per 10,000 quarter days at risk (left axis). In treatment pens an initial observation period of months 1-3
was followed by the intervention period during months 4-13 when cases of subclinical IMI received 8-day therapy, while control pens were
observed with no intervention applied for the entire 13 months. Treatment pens top panels, Control pens bottom panels, Farm 1 left panels,
Farm 2 right panels.
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0.00552)], and CC97 [β = 0.00589 (0.00271 – 0.01280)].
Discussion
This study demonstrated a significant increase in bacterio-
logic cure of S. aureus in quarters receiving 8-day pirlimy-
cin therapy during lactation compared to the untreated
quarters. As with previous studies of small numbers of
natural infections [5] these cure proportions should be
interpreted with caution. The small number of IMI caused
by S. aureus in the two herds in our study and the high
proportion of cure among treated quarters also limited
our ability to explore host or strain effects associated with
cure [16]. We observed a significant reduction in duration
of infection in the treatment pens compared to controlpens. Few mastitis control studies have included duration
of infection or a survival function as an outcome. Yet
duration of infection is a critical parameter in modeling
indirect population level effects of interventions such as
antibiotic treatment, vaccination or segregation and cul-
ling [9].
Studies designed to estimate indirect effects of interven-
tions by quantifying species specific IMI incidence rates
are uncommon as they require intensive sampling
schemes [17]. To our knowledge, longitudinal studies of
mastitis control with strain specific estimates of preva-
lence, incidence and transmission parameters have not
been reported previously. Despite extensive sample collec-
tion, the current study is constrained by an issue of lim-
ited data availability with regards to S. aureus IMI, which
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farms. Even so, these data suggest that mastitis transmis-
sion may differ among strains of S. aureus. We also pro-
vide novel data demonstrating the indirect effects of
lactation therapy and the potential impact of treatment-
based interventions on S. aureus mastitis transmission
dynamics.
In both herds new S. aureus IMI emerged in the
absence of observed IMI of the same ST in other
animals. We also observed that a reduction of a domi-
nant strain was followed by emergence and possible
transmission of a novel strain, and thus strain typing
was sufficient to demonstrate that some new infections
were not the result of contagious transmission. This
suggests that in herds with a low S. aureus IMI preva-
lence, (e.g. Herd 2 in this study), a greater proportion of
new IMI may be from extra-mammary sources com-
pared to those resulting from contagious transmission.
Previous authors have demonstrated an association
between non-bovine associated STs and carriage of peni-
cillin resistance [16]. Our finding of ST8 isolates being
penicillin resistant and no antimicrobial resistance
among bovine-associated STs is consistent with this pre-
vious report. ST8 is a human-associated strain that has
been previously reported to cause mastitis in dairy cattle
in Japan, Switzerland, Turkey and the Netherlands
[16,30,31]. To the best of our knowledge this is the first
report of beta-lactam resistant ST8 isolated from dairy
cattle in the United States. The complex relationships
between host-adaptation, carriage of antimicrobial resis-
tance and probability of cure among S. aureus strains
warrants continued study [16].
An important observation from this study is the report
of new S. aureus infections caused by a different strain
type in previously cured quarters. In our study and that
of Luby and Middleton [32], strain typing of pre- and
post-treatment S. aureus isolates provided improved
estimates of cure and re-infection proportions. In the
absence of strain typing we would have under-estimated
the cure proportion (67% instead of 78%) and the
re-infection rate. This contrasts to a prior study where
all non-cured quarters following treatment appeared to
be persistently infected with the pre-treatment strain
[33]. Previous studies on subclinical mastitis suggested
that quarters that had recovered from S. aureus mastitis
were more likely than naive quarters to become infected
with S. aureus [34], and our results support this possibil-
ity. We cannot distinguish between non-cure and cure
followed by re-infection with the same strain type pre-
and post-treatment. This dilemma has been identified
before [33], and may be due to limited strain diversity
commonly observed within herds [13,35]. In addition,
we cannot eliminate the possibility of genetic changes
resulting in a change in PT following treatment althoughthe criteria used for interpretation of banding patterns
were developed to allow for recognition of subtypes that
emerge through a genetic event [22,36]. Finally, the pos-
sibility of carriage of more than one strain and isolation
of different strains pre-treatment and post-treatment has
also been described [37].
Treatment of subclinical mastitis was associated with
lower rates of S. aureus clinical mastitis which we attri-
bute to shorter duration of infection in the treated
group. A reduction in the number of clinical mastitis
cases associated with lactation therapy for subclinical
mastitis is in agreement with some reports [11,38], and
contrasts with others [39]. Reducing the use of antibiotic
treatments for clinical mastitis has been proposed to off-
set the costs of treating subclinical mastitis [40].
Treatment clearly eliminated infections and reduced
prevalence of S. aureus in both herds; however the asso-
ciation between prevalence and incidence could only be
compared between treatment and control groups in
Herd 1. For this herd, we suggest that the positive asso-
ciation between treatment and lower IMI incidence was
through the indirect effect of reduced IMI prevalence.
This is consistent with a causal model for contagious
disease transmission, where reducing duration of infec-
tion and overall prevalence lowers the force of infection
[9]. In a transmission model Barlow et al. previously
predicted that the indirect effect of therapy would
approach zero under scenarios of very low transmission
parameter estimates, for example in herds where post-
milking hygiene is consistently applied and selective
culling of chronically infected cows is implemented [9].
In this field study we observed 36 new IMI per 260,238
quarter days at risk in herd 1, and estimated the trans-
mission parameter β = 0.008 and a positive indirect
effect of treatment in line with our prior model predic-
tions [9].
Transmission parameter estimates for CCs were ‘pooled’
estimates including the respective STs or PTs and PT sub-
types. In the current study, as in a previous study of three
herds [12], it was difficult to separate strain effects from
herd effects because strains were largely herd-specific.
Differences in transmission have been described for two
S. aureus strains that occurred during the same time
period within a single herd [41]. Additional research is
required to quantify differences in transmission probabi-
lities among S. aureus strains associated with bovine mas-
titis, and the potential relevance of these differences to
mastitis control practices. In our data, strains belonging to
the bovine adapted CC 705 appeared to have a higher trans-
mission probability compared to a human adapted ST 8,
suggesting that the greatest indirect effects of S. aureus
control would be realized through elimination of bovine-
adapted strains from herds. Because our results are based
on a small number of IMI from only 2 herds further studies
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and recommendations have been reported for Streptococcus
agalactiae, i.e. a differentiation between bovine and human-
adapted strains, which differ in transmission probability and
in the need to implement stringent control programs [42].
As a research tool, MLST is unambiguous, reproducible,
portable and able to discriminate among bovine and non-
bovine adapted S. aureus strains; however a less expensive
and less time-consuming method would be required for
diagnostic decision making in a clinical setting.
The treatment program used in this study was a research
protocol designed to account for within cow correlation of
infection risk among quarters. It is not expected that intra-
mammary lactation treatment of all quarters in a cow with
IMI in less than 4 quarters would be implemented in a
commercial setting. If shown to be beneficial, lactation the-
rapy would be integrated with other established control
methods. As we have previously described, positive indirect
effects of lactation therapy would be expected only in herds
that have well established mastitis control practices such as
post-milking hygiene and segregation or culling of chroni-
cally infected cows [9].
It is currently uncertain if lactation therapy of subclinical
S. aureus mastitis can be economically justified. Swinkels
et al. [40] have described a partial budget model for estima-
tion of economic benefits of treating subclinical mastitis
caused by S. aureus. Their model was sensitive to estimates
of transmission probability and probability of culling. In
addition, the probability of clinical mastitis was a factor
contributing to the economic benefits of lactation therapy.
Results of our study provide information on the indirect
effects of treatment which might be used to inform add-
itional studies on the potential cost-benefit of lactation
therapy for control of subclinical mastitis in dairy herds.
Conclusion
Treatment of subclinical S. aureus mastitis during lactation
resulted in increased cure, reduced duration of infection,
reduced rates of clinical mastitis and lower new infection
rates. Therefore this is one of the first field studies to quan-
tify positive direct and indirect effects of treating S. aureus
mastitis during lactation. In addition strain specific trans-
mission dynamics and transmission parameters were
demonstrated. Further research on treatment of subclinical
mastitis during lactation is required and future research on
S. aureus epidemiology and control in dairy herds should
include methods to improve our understanding of trans-
mission and host-adaptation of S. aureus strains or clonal
complexes in dairy cattle populations.
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